Voyager Therapeutics Inc., a gene therapy company advancing adeno-associated virus (AAV) treatments for five central nervous system (CNS) disorders, has filed to raise up to $86.3 million in a yet-to-price IPO. The Cambridge, Mass.-based company, formed by Third Rock Ventures, plans to list its shares on Nasdaq under the symbol VYGR.